期刊文献+

Health care-associated hepatitis C virus infection 被引量:5

Health care-associated hepatitis C virus infection
下载PDF
导出
摘要 Hepatitis C virus(HCV)is a blood-borne pathogen that has a worldwide distribution and infects millions of people.Care-associated HCV infections represented a huge part of hepatitis C burden in the past via contaminated blood and unsafe injections and continue to be a serious problem of public health.The present review proposes a panorama of health care-associated HCV infections via the three mode of contamination that have been identified:(1)infected patient to non-infected patient;(2)infected patient to non-infected health careworker(HCW);and(3)infected HCW to non infected patient.For each condition,the circumstances of contamination are described together with the means to prevent them.As a whole,the more important risk is represented by unsafe practices regarding injections,notably with the improper use of multidose vials used for multiple patients.The questions of occupational exposures and infected HCWs are also discussed.In terms of prevention and surveillance,the main arm for combating care-associated HCV infections is the implementation of standard precautions in all the fields of cares,with training programs and audits to verify their good application.HCWs must be sensitized to the risk of blood-borne pathogens,notably by the use of safety devices for injections and good hygiene practices in the operating theatre and in all the invasive procedures.The providers performing exposed-prone procedures must monitor their HCV serology regularly in order to detect early any primary infection and to treat it without delay.With the need to stay vigilant because HCV infection is often a hidden risk,it can be hoped that the number of people infected by HCV via health care will decrease very significantly in the next years. Hepatitis C virus (HCV) is a blood-borne pathogen that has a worldwide distribution and infects millions of people. Care-associated HCV infections represented a huge part of hepatitis C burden in the past via contaminated blood and unsafe injections and continue to be a serious problem of public health. The present review proposes a panorama of health care-associated HCV infections via the three mode of contamination that have been identified: (1) infected patient to non-infected patient; (2) infected patient to non-infected health care worker (HCW); and (3) infected HCW to non infected patient. For each condition, the circumstances of contamination are described together with the means to prevent them. As a whole, the more important risk is represented by unsafe practices regarding injections, notably with the improper use of multidose vials used for multiple patients. The questions of occupational exposures and infected HCWs are also discussed. In terms of prevention and surveillance, the main arm for combating care-associated HCV infections is the implementation of standard precautions in all the fields of cares, with training programs and audits to verify their good application. HCWs must be sensitized to the risk of blood-borne pathogens, notably by the use of safety devices for injections and good hygiene practices in the operating theatre and in all the invasive procedures. The providers performing exposed-prone procedures must monitor their HCV serology regularly in order to detect early any primary infection and to treat it without delay. With the need to stay vigilant because HCV infection is often a hidden risk, it can be hoped that the number of people infected by HCV via health care will decrease very significantly in the next years.
出处 《World Journal of Gastroenterology》 SCIE CAS 2014年第46期17265-17278,共14页 世界胃肠病学杂志(英文版)
  • 相关文献

参考文献13

  • 1J Richard Thompson.Emerging therapeutic options for the management of hepatitis C infection[J].World Journal of Gastroenterology,2014,20(23):7079-7088. 被引量:3
  • 2Neelam Marwaha,Suchet Sachdev.Current testing strategies for hepatitis C virus infection in blood donors and the way forward[J].World Journal of Gastroenterology,2014,20(11):2948-2954. 被引量:9
  • 3Celal Ayaz,Mustafa Kemal Celen,Ugur Nedim Yuce,Mehmet Faruk Geyik.Efficacy and safety of pegylated-interferon α-2a in hemodialysis patients with chronic hepatitis C[J].World Journal of Gastroenterology,2008,14(2):255-259. 被引量:5
  • 4E. Sagnelli,T. Santantonio,N. Coppola,M. Fasano,M. Pisaturo,C. Sagnelli.Acute hepatitis C: clinical and laboratory diagnosis, course of the disease, treatment[J].Infection.2014(4)
  • 5Fabrizio Fabrizi,Paul Martin.Health Care–Associated Transmission of Hepatitis B and C Viruses in Hemodialysis Units[J].Clinics in Liver Disease.2010(1)
  • 6Hao Wu,Bo Shen.Health Care–Associated Transmission of Hepatitis B and C Viruses in Endoscopy Units[J].Clinics in Liver Disease.2010(1)
  • 7Joseph F. Perz,Nicola D. Thompson,Melissa K. Schaefer,Priti R. Patel.US Outbreak Investigations Highlight the Need for Safe Injection Practices and Basic Infection Control[J].Clinics in Liver Disease.2010(1)
  • 8Mario Fusco,Enrico Girardi,Pierluca Piselli,Raffaele Palombino,Jerry Polesel,Carmela Maione,Paola Scognamiglio,Francesco Aurelio Pisanti,Mariacarmela Solmone,Pietro Di Cicco,Giuseppe Ippolito,Silvia Franceschi,Diego Serraino.Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer[J].European Journal of Cancer.2008(6)
  • 9Labus, B,Sands, L,Rowley, P,Azzam, I A,Holmberg, S D,Perz, J F,Patel, P R,Fischer, G E,Schaefer, M.Acute Hepatitis C Virus Infections Attributed to Unsafe Injection Practices at an Endoscopy Clinic - Nevada, 2007[J].MMWR Morbidity and Mortality Weekly Report.2008(19)
  • 10Jane L. Perry,Richard D. Pearson,Janine Jagger.Infected health care workers and patient safety: A double standard[J].AJIC: American Journal of Infection Control.2006(5)

二级参考文献22

  • 1Ioan Sporea,Alina Popescu,Roxana ■irli,Ovidiu Golea,CameliaTotolici,Mirela Dǎnilǎ,Corina Vernic.Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis[J].World Journal of Gastroenterology,2006,12(26):4191-4194. 被引量:2
  • 2XIE Li,WU Xiao-dong,HUANG De-zhuang,CHEN Hai-lun,HE Li-xiang,WANG Jian,HAN Da-kang.Clinical application and analysis of hepatitis C virus NS3 antigen detection by ELISA in human serum[J].Chinese Medical Journal,2007(4):294-299. 被引量:4
  • 3Fred Poordad,Jean–Pierre Bronowicki,Stuart C. Gordon,Stefan Zeuzem,Ira M. Jacobson,Mark S. Sulkowski,Thierry Poynard,Timothy R. Morgan,Cliona Molony,Lisa D. Pedicone,Heather L. Sings,Margaret H. Burroughs,Vilma Sniukiene,Navdeep Boparai,Venkata S. Goteti,Clifford A. Brass,Janice K. Albrecht,Bruce R. Bacon.Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir[J].Gastroenterology.2012(3)
  • 4F. Poordad,D. Dieterich.Treating hepatitis C: current standard of care and emerging direct‐acting antiviral agents[J].Journal of Viral Hepatitis.2012(7)
  • 5Paul Y Kwo,Eric J Lawitz,Jonathan McCone,Eugene R Schiff,John M Vierling,David Pound,Mitchell N Davis,Joseph S Galati,Stuart C Gordon,Natarajan Ravendhran,Lorenzo Rossaro,Frank H Anderson,Ira M Jacobson,Raymond Rubin,Kenneth Koury,Lisa D Pedicone,Clifford A Brass,Eirum Chaudhri,Janice K Albrecht.Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial[J].The Lancet.2010(9742)
  • 6Syria Laperche.Multinational assessment of blood‐borne virus testing and transfusion safety on the African continent[J].Transfusion.2012(4)
  • 7Shuijun Gu,Jun Liu,Huijun Zhang,Baoluo Gu,Hanjiang Lai,Hongliang Zhou,Chaoqi He,Yingying Chen.Core antigen tests for hepatitis C virus: a meta-analysis[J].Molecular Biology Reports.2012(8)
  • 8ShimianZou,Kerri A.Dorsey,Edward P.Notari,Gregory A.Foster,David E.Krysztof,FatemehMusavi,Roger Y.Dodd,Susan L.Stramer.Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing[J].Transfusion.2010(7)
  • 9Raymond P. Goodrich,Suzann Doane,Heather L. Reddy.Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products[J].Biologicals.2009(1)
  • 10N.A. Mufti,A.C. Erickson,A.K. North,D. Hanson,L. Sawyer,L.M. Corash,L. Lin.Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC[J].Biologicals.2009(1)

共引文献15

同被引文献39

引证文献5

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部